AU6773598A - Treatment of gastrointestinal disease with ppar modulators - Google Patents
Treatment of gastrointestinal disease with ppar modulatorsInfo
- Publication number
- AU6773598A AU6773598A AU67735/98A AU6773598A AU6773598A AU 6773598 A AU6773598 A AU 6773598A AU 67735/98 A AU67735/98 A AU 67735/98A AU 6773598 A AU6773598 A AU 6773598A AU 6773598 A AU6773598 A AU 6773598A
- Authority
- AU
- Australia
- Prior art keywords
- treatment
- gastrointestinal disease
- ppar modulators
- ppar
- modulators
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/06—Gastro-intestinal diseases
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4137297P | 1997-03-26 | 1997-03-26 | |
US60041372 | 1997-03-26 | ||
PCT/US1998/005852 WO1998043081A1 (en) | 1997-03-26 | 1998-03-25 | Treatment of gastrointestinal disease with ppar modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
AU6773598A true AU6773598A (en) | 1998-10-20 |
Family
ID=21916159
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU67735/98A Abandoned AU6773598A (en) | 1997-03-26 | 1998-03-25 | Treatment of gastrointestinal disease with ppar modulators |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU6773598A (en) |
WO (1) | WO1998043081A1 (en) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9822473D0 (en) | 1998-10-16 | 1998-12-09 | Glaxo Group Ltd | Chemical compounds |
WO2000053563A1 (en) * | 1999-03-11 | 2000-09-14 | Nuclear Receptor Research Limited | Novel ligands of nuclear receptors ppar's |
GB9917405D0 (en) * | 1999-07-23 | 1999-09-22 | Univ Dundee | Methods of treatment and drug screening methods |
DE60005973T2 (en) * | 1999-08-27 | 2004-05-13 | Eli Lilly And Co., Indianapolis | BIARYL-OXA (THIA) ZOL DERIVATIVES AND THEIR USE AS PPARS MODULATORS |
US6159734A (en) * | 2000-01-18 | 2000-12-12 | Isis Pharmaceuticals, Inc. | Antisense modulation of peroxisome proliferator-activated receptor gamma expression |
EP1911462A3 (en) | 2001-01-26 | 2011-11-30 | Schering Corporation | Compositions comprising a sterol absorption inhibitor |
EP1357914A2 (en) * | 2001-02-02 | 2003-11-05 | SmithKline Beecham Corporation | Treatment of ppar mediated diseases |
JPWO2002080899A1 (en) * | 2001-03-30 | 2005-01-06 | エーザイ株式会社 | Gastrointestinal disease treatment |
GB0127916D0 (en) * | 2001-11-21 | 2002-01-16 | Rowett Res Inst | Method |
EP1733237A2 (en) * | 2004-03-26 | 2006-12-20 | Bayer HealthCare AG | Diagnostics and therapeutics for diseases associated with peroxisome proliferative activated receptor alpha (ppara) |
ITMI20041825A1 (en) * | 2004-09-24 | 2004-12-24 | Medestea Res & Production Srl | RECEPTOR AGONISTS ACTIVATING THE PROLIFERATION OF PEROXYSOMES, USEFUL IN THE PREVENTION OR TREATMENT OF GASTRITIS |
ITRM20050389A1 (en) | 2005-07-22 | 2007-01-23 | Giuliani Spa | COMPOUNDS AND THEIR SPECIFIC SALTS FOR PPAR RECEPTORS AND RECEPTORS FOR EGF AND THEIR USE IN MEDICAL FIELDS. |
ITRM20050390A1 (en) | 2005-07-22 | 2007-01-23 | Giuliani Spa | COMPOUNDS AND THEIR SPECIFIC SALTS FOR PPAR RECEPTORS AND RECEPTORS FOR EGF AND THEIR USE IN MEDICAL FIELDS. |
AU2007266714B2 (en) | 2006-01-18 | 2013-03-14 | Evolva Sa | PPAR modulators |
MX2009007669A (en) | 2007-01-18 | 2011-12-08 | Evolva Sa | Substituted 1,3-dioxanes and their uses. |
US20100273824A1 (en) | 2007-01-18 | 2010-10-28 | Evolva Sa | Substituted 1,3-dioxanes and their uses |
WO2008104305A1 (en) * | 2007-02-27 | 2008-09-04 | Bayer Schering Pharma Aktiengesellschaft | Pygm as a biomarker for ppara modulators |
UA107562C2 (en) | 2008-12-05 | 2015-01-26 | METHOD OF TREATMENT OF PSORIASIS | |
JP5645851B2 (en) | 2009-02-16 | 2014-12-24 | ノグラ ファーマ リミテッド | How to treat hair-related conditions |
JP5180978B2 (en) * | 2010-02-01 | 2013-04-10 | 花王株式会社 | Screening method for anti-obesity substances |
US20130156720A1 (en) | 2010-08-27 | 2013-06-20 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
GB201112091D0 (en) | 2011-07-14 | 2011-08-31 | Gt Biolog Ltd | Bacterial strains isolated from pigs |
GB201117313D0 (en) | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
EA030762B1 (en) | 2012-02-09 | 2018-09-28 | Ногра Фарма Лимитед | Methods of treating fibrosis |
MX2014012652A (en) | 2012-04-18 | 2014-11-25 | Nogra Pharma Ltd | Methods of treating lactose intolerance. |
GB201306536D0 (en) | 2013-04-10 | 2013-05-22 | Gt Biolog Ltd | Polypeptide and immune modulation |
AR103260A1 (en) | 2014-12-23 | 2017-04-26 | 4D Pharma Res Ltd | IMMUNE MODULATION |
KR20170091157A (en) | 2014-12-23 | 2017-08-08 | 4디 파마 리서치 리미티드 | Pirin polypeptide and immune modulation |
SI3307288T1 (en) | 2015-06-15 | 2019-11-29 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
EP3206700B1 (en) | 2015-06-15 | 2019-06-05 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
MA41010B1 (en) | 2015-06-15 | 2020-01-31 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
MA41060B1 (en) | 2015-06-15 | 2019-11-29 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
SG10201912323VA (en) | 2015-06-15 | 2020-02-27 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
EP3363446A1 (en) | 2015-11-20 | 2018-08-22 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
GB201520497D0 (en) | 2015-11-20 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
GB201520631D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
GB201520638D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
GB201612191D0 (en) | 2016-07-13 | 2016-08-24 | 4D Pharma Plc | Compositions comprising bacterial strains |
TW201733601A (en) | 2016-03-04 | 2017-10-01 | 4D製藥有限公司 | Compositions comprising bacterial strains |
TW201821093A (en) | 2016-07-13 | 2018-06-16 | 英商4D製藥有限公司 | Compositions comprising bacterial strains |
GB201621123D0 (en) | 2016-12-12 | 2017-01-25 | 4D Pharma Plc | Compositions comprising bacterial strains |
WO2018215760A1 (en) | 2017-05-22 | 2018-11-29 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
MA41708A (en) | 2017-05-24 | 2020-04-08 | 4D Pharma Res Ltd | COMPOSITIONS CONTAINING BACTERIAL STRAINS |
EP3638271B1 (en) | 2017-06-14 | 2020-10-14 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
WO2018229236A2 (en) | 2017-06-14 | 2018-12-20 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
JP2022519654A (en) | 2019-02-08 | 2022-03-24 | ノグラ ファーマ リミテッド | Methods for Producing 3- (4'-Aminophenyl) -2-MethoxyPropionic Acid, and its analogs and intermediates |
CN112168820B (en) * | 2019-07-05 | 2023-09-29 | 中国科学院生物物理研究所 | Application of SRCAP ATPase inhibitor in colorectal cancer treatment |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2269897A (en) * | 1992-08-13 | 1994-02-23 | Merck Frosst Canada Inc | Assay to detect peroxisome proliferator activity |
-
1998
- 1998-03-25 AU AU67735/98A patent/AU6773598A/en not_active Abandoned
- 1998-03-25 WO PCT/US1998/005852 patent/WO1998043081A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO1998043081A1 (en) | 1998-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU6773598A (en) | Treatment of gastrointestinal disease with ppar modulators | |
AU4050797A (en) | Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators | |
AU5872696A (en) | Endoscope | |
AU7268298A (en) | Differential treatment of prosthetic devices | |
AU3075895A (en) | Endoscope | |
AU1450900A (en) | Methods of treatment of type 2 diabetes | |
AU6418498A (en) | Human genes | |
AU7592998A (en) | Modulators of tissue regeneration | |
AU5899798A (en) | Aminoacyl sulfamides for the treatment of hyperproliferative disorders | |
AU6928098A (en) | Optical modulator | |
AU3596199A (en) | Treatment of celiac disease | |
AU8329498A (en) | Diagnosis of edema | |
AU3322795A (en) | Endoscope | |
AU1184399A (en) | Therapeutic molecules | |
AU7058000A (en) | 13 human colon and colon cancer associated proteins | |
AU7592398A (en) | Human gp12 homolog | |
AU2105897A (en) | Organic photoconductor and treatment therefor | |
AU1645599A (en) | Human matrilin-3 | |
AU8155898A (en) | Human preprotachykinin b | |
AU8557598A (en) | Treatment of fluids | |
AU696976B2 (en) | Effluent treatment | |
AU4124497A (en) | Treatment of diabetes | |
AUPO948197A0 (en) | Diagnosis of parasites | |
AUPO495397A0 (en) | Diagnosis of parasites | |
AUPO632997A0 (en) | Diagnosis of parasites |